| ALK | anaplastic lymphoma kinase |
| NSCLC | non-small cell lung cancer |
| TKI | tyrosine kinase inhibitor |
| TNT TP53 |
time-to-next-treatment tumor protein p53 |
| PFS | progression-free survival |
| OS | overall survival |
| ALK | anaplastic lymphoma kinase |
| NSCLC | non-small cell lung cancer |
| TKI | tyrosine kinase inhibitor |
| TNT TP53 |
time-to-next-treatment tumor protein p53 |
| PFS | progression-free survival |
| OS | overall survival |